The Chisum Patent Academy’s next New York City seminar will be held on February 20 – 22, 2013.

Location:

American Elm conference room (Suite 503), Helmsley Park Lane Hotel, 36 Central Park South, New York, NY 10019.

Schedule:

The Chisum Patent Academy will hold its next Advanced Patent Law Seminars in New York City (February 2013) and Seattle (July/August 2013).

Each three-day seminar is limited to ten (10) attendees. Our seminars are conducted in interactive, round-table style to maximize opportunities for discussion and questioning. All sessions are co-taught by Donald Chisum and Janice Mueller.

Seminar Coverage:

The NYC 2013 seminar will focus in great depth on two timely and controversial patent law topics: patent claim interpretation and active inducement (particularly in the context of multi-actor method claims). We will also cover America Invents Act developments including the USPTO’s final rules on first inventor to file (taking effect three weeks after our seminar); preliminary injunctions and design patents; and inequitable conduct decisions post-Therasense.

Topics include:

  • Claims as the “Name of the Game”: Lessons on Patent Claim Drafting and Interpretation from Recent Federal Circuit Cases.
  • Active Inducement, Method and System Claims, and Joint Infringement.
  • America Invents Act’s “First Inventor to File” Principle on the Eve of Its Effective Date (March 16, 2013).
  • Preliminary Injunctions and Design Patents: Apple v. Samsung.
  • Inequitable Conduct: Decisions Since Therasense.

The Chisum Patent Academy will apply for 18 hours of CLE accreditation per seminar in those states where we conduct seminars. Where state bars require, we submit attendees’ names as they are listed on the sign-in sheet. If you are seeking CLE credit for a state other than where that seminar is being held, please apply directly to the appropriate state bar.

Registration Fee:

$2,750 per attendee.

Additional details about the New York City seminar (February 20-22, 2013).

  Print This Post   Email This Post

acilifescicollabAt American Conference Institute’s 17th Advanced Forum on Life Sciences Collaborative Agreements and Acquisitions, a seasoned faculty of business development, licensing, and alliance management executives from top life sciences companies like Pfizer, AstaZeneca, GlaxoSmithKline, Sanofi Pasteur, Novartis, and Bayer will help you enable your company to advance its key growth strategies.

In just two days, these experienced professionals will share:

  • In-depth analysis of recent trends in collaboration
  • Valuable strategies for managing fruitful alliances
  • Best practices for structuring deals to maximally benefit all parties
  • Tips for working with academic institutions
  • Methods for crafting effective termination provisions, and much more

You will also receive expert instruction on how to avoid antitrust problems directly from the Federal Trade Commission, mitigating the effects of patent reform on deal making, spreading and limiting risk, and exposing deal-killing IP problems before they wreak havoc.

In addition, exclusive post-conference workshops will cover:

  • Strategies for executing due diligence procedures, like managing legal risks associated with collaborations, comparing differing metrics used in M&A deals, and crafting checklists to perform effectively IP diligence.
  • The collaborative agreement review and strategy session where attendees can compare redacted collaboration contracts to develop best practices for drafting effective agreements.

Take this opportunity to get the most current and comprehensive information and advice regarding strategic partnering agreements in an environment that will provide valuable networking opportunities.

Register now for this timely event by calling 888.224.2480, by fax at877.927.1563, or register online at  americanconference.com/collaborations.

————-

*Patent Baristas readers are entitled to a discount when referencing the code: PB 200

  Print This Post   Email This Post

Now is your chance to join a select group of technological game-changers whose ingenuity will be showcased in a celebration of innovation.

Cutting-edge innovators can apply for a place among the exhibitors at the Department of Commerce’s United States Patent and Trademark Office (USPTO) Innovation Expo, to be held on the agency’s campus in Alexandria, Va., June 20-22, 2013.

Exhibits will showcase the latest technological developments from America’s innovators affiliated with large corporations, small businesses, academic institutions, government agencies and the independent inventor community. A diverse range of technologies will be represented at the Expo.

IE2012_websiteheaderThe Expo will also demonstrate the vital role America’s intellectual property system and the United States Patent and Trademark office play in promoting and protecting innovation, a role that contributes greatly to America’s competitiveness and economic prowess in the global economy.

The application deadline is February 13, 2013. Exhibition slots will be awarded to qualified U.S. patent owners on a rolling basis. Space is limited, so apply now.

Applications will be reviewed by an independent committee made up of representatives from some of the most important and respected intellectual property organizations.

For more information see the Innovation Expo FAQ or contact innovationexpo@uspto.gov.

  Print This Post   Email This Post

The Comprehensive Guide to Patent Reform

Who:                Patent practitioners needing a reminded how the world has changed
What:               The critical industry forum on The Leahy-Smith America Invents Act
When:              Wednesday, January 23 to Thursday, January 24, 2013
Where:             Doubletree Suites Times Square, New York, NY

March 15, 2013 is the last day for the decades-old U.S. patent regime, and for patent attorneys, this date is every bit as foreboding for them as it was for Caesar himself. The America Invents Act (AIA) is ushering in a raft of new rules and spawning regulations that upend generations of established prosecution and litigation practices, leaving no small amount of fear and consternation in its wake. But the Act also presents practitioners with opportunities to enhance their IP portfolios’ value and undermine rivals’ patents – thanks to a bevy of new pre-and post-issuance procedures.

Nevertheless, the full effects of countless nuances sprinkled throughout the AIA and the full implications of regulations promulgated under it remain unknown, and patent practitioners are left with a multitude of questions regarding the potential ramifications for their craft. With so much at stake, you must develop a plan to address both the changes already in effect and those whose coming implementation looms just one day past that fateful date – the Ides of March.

American Conference Institute’s 2nd Comprehensive Guide to Patent Reform once again unites experienced in-house counsel from top innovators, private practice experts, and senior officials from the USPTO to answer patent professionals’ most pressing questions, including:

  • What does “first to file” actually mean under the AIA requirements? Which system can you or should you file under – the current first to invent or the new first to file (or both)? And how do you avoid first-to-file bubble filings before 3/15/2013?
  • When can on-sale and public use activity be considered prior art? Has secret §102(f) prior art been eliminated?
  • Do you need to include best mode in the application or not and what happens if you don’t? Is best mode completely toothless now? How will examiners be able to address the best mode issue?
  • What will be required in the PGR process? What type of discovery? Expert witnesses? How do the estoppel provisions alter your analysis of whether to engage in the PGR system?
  • What estoppel provisions are associated with IPRs and how are these different from the inter partes reexamination provisions? When do you file a 3rd party parallel IPR?

Register by calling 888-224-2480 or faxing your registration form to 877-927-1563 or registering on-line atwww.americanconference.com/patentreform.

  Print This Post   Email This Post

Boon or Bane for Technological Innovation?: Software Patents

Pure software patents have become the focus of a heated innovation policy debate. On the one hand, new technological innovation is now a commonplace feature of our lives.  On the other hand, the high-tech industry seems awash in patent litigation, especially in the “smart phone war” between Apple, Samsung, Google, Microsoft, and other high-tech firms.

As a result, commentators now complain about the “problem of software patents.”

The IP Practice Group at the Federalist Society for Law and Public Policy Studies is now hosting a teleforum thatb will consider whether software patents advance development of new technological innovation or hinder innovation. The panelists represent all viewpoints on this topic and bring academic, legal and industry experiences to the issue.

Featuring:

Agenda:

Call begins at 2:00 p.m. Eastern Time on Tuesday, November 6, 2012.

Registration details:

Teleforum calls are open to all dues paying members of the Federalist Society. To become a member, sign up here. As a member, you should receive email announcements of upcoming Teleforum calls which contain the conference call phone number. If you are not receiving those email announcements, please contact them at 202-822-8138.

Related Materials

  Print This Post   Email This Post

Conference on the Life Cycle of Orphan Drug Development & Commercialization

Conducting Effective Orphan Drug Research and Clinical Trials to Expedite Orphan Drug Approval

When:    January 16-18, 2013
Where:   Boston, MA

Key Topics

Improve current rare disease research methods used in early stages of orphan drug development with Genzyme
Evaluate where the rare disease research units fit in the portfolio for large and niche pharma companies with Pfizer
Utilize translational medicine to be effective in orphan drug development with Vertex
Collaborate with patient advocacy groups to increase patient recruitment in clinical trials with BioMarin
Review the FDA Safety and Innovation Act and its impact on orphan drug reserach and development with National Organization for Rare Disorders

Key Features

2 Pre-Conference Workshops on January 16, 2013

  1. Pre-Conference Workshop A: Integrating Gene Therapy and Stem-Cell Therapy Treatments in Rare Disease Clinical Trials with ReGenX Biosciences, LLC
  2. Pre-Conference Workshop B: Exploring New Solutions to Reduce the Orphan Drug Funding Gap with Asklepion

Event Focus

The orphan drug and rare disease industry is one of the hottest topics in modern day medicine. With blockbuster drugs coming off patent, there is a great need for pharmaceutical companies to diversify their portfolios by exploring niche markets. The increasing presence of high-profile manufacturers in the orphan drug industry provides these companies with this opportunity.

The Life Cycle of Orphan Drug Development & Commercialization Conference will focus on the current landscape of rare disease and orphan drug development, different forms of structural based drug designs, and specifically designed clinical trials.  Through these clinical trials, and by having connected to the right patients to participate, will increase productivity and expedite orphan drug approval and commercialization of the final product.

By attending this conference, delegates will gain a comprehensive view of the orphan drug and rare disease industry and will have a clearer understanding of the natural histories of rare diseases and how to most effectively treat them. Through maximizing translational research methods to evaluate bio-markers and surrogate markers in the patient’s body, this will assist in the design of orphan drug clinical trials resulting in quickly obtaining results and being able to send the orphan drug in for FDA approval.

Attending This Conference Will Enable You To:

  1. Assess the current rare disease department within the pharmaceutical industry
  2. Analyze current orphan drug developments and treatment methods in clinical trials
  3. Select the optimal patient target market to engage in rare disease clinical trials
  4. Review orphan drug regulations and accelerate orphan drug approval
  5. Address the importance of reimbursement and commercialization in the orphan drug industry

Industry leaders attending this conference will benefit from a dynamic presentation format consisting of workshops, panel discussions, and industry-specific case studies that provide accurate, real-world knowledge. Attendees will experience highly interactive conference sessions, 10-15 minutes of Q&A time after each presentation, 4+ hours of networking, and exclusive online access to materials post-event.

Register here.

  Print This Post   Email This Post

A special treat this week is a great podcast by Professor Richard A. Epstein, in which he offers his usual brilliant and insightful commentary on the patent system. As is to be expected, Richard packs about 3 hours of intellectual content into a 1-hour event.

To listen, please right click on the audio file you wish to hear and then select “Save Link As…” or “Save Target As…” After you save the audio file to your computer, you can then listen to it in your audio player of choice.

  Patent Rights: A Spark or Hindrance for the Economy? - MP3
Running Time: 00:54:30

Critics, including Judge Richard Posner, have argued that the patent system has led to excessive patenting, too much litigation, and unwarranted costs for consumers. Patent defenders have responded that with every spike in innovation comes a corresponding increase in the number of patent suits, and efforts to weaken patent rights will inevitably lead to less innovation.

Despite the passage of the America Invents Act,  the debate over intellectual property continues after a string of high profile patent infringement suits in the smartphone industry.

Would reduced patent rights diminish U.S. competitiveness and depress innovation? In a diversified economy, should so-called “non-practicing entities” (NPEs) have fewer patent rights than those that manufacture their inventions?

Featuring:

  • Prof. Richard A. Epstein, Laurence A. Tisch Professor of Law, New York University School of Law
  • Prof. Adam Mossoff, Professor of Law, George Mason University School of Law
  • Moderator: Mr. Dean Reuter, Vice President & Director of Practice Groups, The Federalist Society

*via Adam Mossoff and the IP Practice Group at the Federalist Society for Law and Public Policy Studies.

 

  Print This Post   Email This Post

The U.S. Commerce Department’s United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO)  announced publication of a classification system meant to speed the patent granting process for applicants to both Offices.

The Cooperative Patent Classification (CPC) system and finalized CPC definitions are now available in advance of the January 1, 2013, official launch. The CPC is a joint USPTO-EPO project aimed at developing a common classification system for technical documents in particular patent publications, which will be used by both offices in the patent granting process.

The CPC system, which includes approximately 250,000 classification symbols based on the International Patent Classification (IPC) system, will enable users to conduct efficient prior art searches and incorporate the best classification practices of both the U.S. and European systems. It will also enhance efficiency through work-sharing initiatives designed to reduce unnecessary duplication of work.

Why CPC?

The EPO and USPTO both have highly developed patent classification systems. CPC is an ambitious harmonization effort to bring the best practices from each Office together. In fact, most U.S. patent documents are already classified in ECLA. The conversion from ECLA to CPC at the EPO will ensure IPC compliance and eliminate the need for the EPO to classify U.S. patent documents. At the USPTO, the conversion will provide an up-to date classification system that is internationally compatible.

What is CPC?

The Cooperative Patent Classification (CPC) effort is a joint partnership between the USPTO and the EPO where the Offices have agreed to harmonize their existing classification systems (ECLA and USPC, respectively) and migrate towards a common classification scheme. This is a strategic decision by both offices and is seen as an important step towards advancing harmonization efforts currently being undertaken through the IP5’s Common Hybrid Classification (CHC) project.

The migration to CPC will be developed based in large part on the existing European Classification System (ECLA) and will be modified to ensure compliance with the International Patent Classification system (IPC) standards administered by the World Intellectual Property Organization (WIPO).

Since October 2010, the USPTO and EPO have worked jointly to develop the CPC. The results of their work are now being made available through a CPC launch package that includes the complete CPC system, any finalized CPC definitions and a CPC-to-IPC concordance.

The CPC definitions will be available for every CPC subclass and contain a description of the technical subject matter covered in the subclass. Eventually, each CPC subclass will have a corresponding CPC definition that will be continuously maintained. The CPC-to-IPC concordance will help users find the relevant IPC area on which the CPC is based.

For more detailed information about the new classification system, including downloadable sections, CPC definitions and concordances, please visit the official CPC website.

See also:  Moving towards a global patent system

  Print This Post   Email This Post